VCNXOTCPharmaceutical PreparationsFiscal year ends December 31
VACCINEX, INC.
Financials through Q4 FY2024, quarter ended Dec 31, 2024Last filing: 10-K on Apr 15, 2025
$1.00−0.01 (-0.99%)
Close on Oct 19, 2026
- Market cap
- $3.22M
- P/E (TTM)
- –
- Dividend yield
- –
VACCINEX, INC. revenue by segment
By business segment
By product or service
By region
From the segment and revenue-disaggregation notes of Vaccinex's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.